Sanum Kashif, Zahid Khan
ABSTRACT
Objective: To compare the perioperative blood loss in patients undergoing hip arthroplasty for femur neck fractures with and without administering tranexamic acid before surgical incision.
Study Design: Comparative Interventional study.
Place and Duration of Study: The study was conducted at Orthopedic Department of Indus Hospital Karachi, from 1st January to 30th June 2015.
Materials and Methods: After ethical committee approval, sixty patients, scheduled for hip arthroplasty were included in this study. Patients were randomly allocated into two groups. Thirty patients in Group A (Tranexamic acid) treated with tranexamic acid with 15mg/kg dose in 10 ml syringe and Group B were given an equal volume of saline before surgery. In both groups, blood loss was calculated. The need for blood transfusion as well as the amount of blood required was also noted. In both the groups, hematocrit was measured on 5th post-operative.
Results: A total of sixty patients (mean age 65.33±9.50 years), scheduled for hip arthroplasty, were included. There were 26 (43.3%) male and 34 (56.7%) female patients. Patients were divided into two equal groups, Group A (Tranexamic acid) and Group B (Normal Saline). Postoperative mean estimated blood loss was significantly reduced in Group A than group B (203.8±141.81 vs. 281.6±130.31 p=0.031).
Conclusion: Tranexamic acid is a cost-effective and safe means of minimizing perioperative blood loss and reduction in hemoglobin concentration in hip arthroplasty.
Key Words: Blood Loss, Hemoglobin Level, Hip Arthroplasty, Postoperative, Tranexamic Acid.
How to cite this: Kashif S, Khan Z. Comparison of Perioperative Blood Loss with and without Tranexamic Acid in Hip Arthroplasty. Life and Science. 2022; 3(1): 20-24. doi: http://doi.org/10.37185/LnS.1.1.196
Read PDFLife and Science is recognized by Pakistan Medical and Dental Council (PM&DC), Islamabad, Pakistan
All the articles published in Life and Science are licensed under a
Creative Commons Attribution-NonCommercial 4.0 International License